Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Brain & Spinal Cord Tumor
0 Years and older, Male and Female
GTM-101 (primary)
NCI-2020-13272
Summary
The objectives of this registry study are to evaluate real-world clinical outcomes and
patient reported outcomes that measure the effectiveness and safety of STaRT.
Objectives
Patients (N=600) with surgically resected (R) brain tumors of any pathology who have
undergone STaRT are eligible. Data collected will include local control, overall survival,
QOL, neurocognition, functional decline, and surgical and radiation associated AE's. Data
will be collected at 1, 3, 6, 9,12, 18 and 24 months, then every 6 months through 5 years.
RESULT: Data will be used to benchmark clinical outcomes of STaRT therapy and allow for
comparisons to existing standard-of-care treatments. This will be the first observational
registry study of R+STaRT, delivered by Cs-131 sources in permanently implanted resorbable
collagen tile carriers. The outcome measures captured will allow for evaluation of the
potential risks and benefits of this treatment approach for patients in a real-world setting.
Eligibility
- Patients who undergo maximum safe resection of intracranial neoplasm(s) AND implantation of GammaTiles.
- Willing and able to provide informed consent and to participate in all evaluations.
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.